Biotechnology
Filter News
Found 7,260 articles
-
Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People With Advanced Lung Cancer
7/19/2018
Genentech announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS)
-
Synteract Augments Executive Team with Cheryl Murphy as Senior Vice President, Clinical Development
7/19/2018
Synteract, an innovative contract research organization (CRO) providing full-service, Phase I-IV services enabling biopharma companies to bring new medicines to market, has added Cheryl Murphy as senior vice president, Clinical Development to its executive team.
-
Provention Bio Announces Closing of Upsized Initial Public Offering
7/19/2018
Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of its initial public offering of shares of its common stock at a public offering price of $4.00 per share on July 19, 2018.
-
Joseph E. Whitters Appointed to Accuray Board of Directors
7/19/2018
Accuray Inc.(NASDAQ: ARAY) announced today the appointment of Joseph E. Whitters to the company's Board of Directors, effective as of July 16, 2018. In addition, he will serve on the Board's Audit Committee. With Mr. Whitters' appointment, the Accuray Board has been expanded to eight members.
-
BioPharmX Announces FDA Grant of CARC Waiver and Post-Hoc Analysis for BPX-01
7/19/2018
BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that the U.S. Food and Drug Administration has waived its requirement for a dermal carcinogenicity study for BPX-01, eliminating several years of non-clinical research normally required for FDA review.
-
Asana BioSciences Initiates Phase 2b Study of ASN002 in Patients with Moderate-to-Severe Atopic Dermatitis (RADIANT)
7/19/2018
Asana Biosciences, a clinical stage biopharmaceutical company focused on discovery and development of novel targeted investigational medicines in Immunology/Inflammation and Oncology, today announced initiation of a Phase 2b study of ASN002, an oral JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis (AD).
-
Two well-known pharmaceutical companies made Fortune Magazine’s 2018 top 100 Best Workplaces for Millennials.
-
In April Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. This morning Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.
-
Despite President Trump circling around semi-regularly to bash the pharmaceutical industry and drug prices, biotech stocks seem to be doing pretty well. The Nasdaq Biotechnology ETF, called the IBB, is up about 17 percent so far this year.
-
French biotech company Servier is setting up shop in Boston following its April deal to acquire Shire’s oncology business for $2.4 billion.
-
Pfizer and Eli Lilly released results from its 16-week Phase III clinical trial in patients with osteoarthritis (OA) pain receiving a subcutaneous dose of tanezumab. The drug hit all three co-primary endpoints.
-
Rubius Therapeutics, based in Cambridge, Massachusetts, has set the price of its initial public offering at $23 per share.
-
Maryland-based Neuraly surged forth from the startup gate with $36 million in Series A funding that will finance the company’s research into the development of therapies for neurodegenerative disorders.
-
HIV patients have some good news this morning. The U.S. Food and Drug Administration approved Janssen Pharmaceutical’s Symtuza, the first and only complete darunavir-based single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1).
-
Absence epilepsy is the most common type of seizure disorder in children and is the focus of a new neurology study at Baylor College of Medicine and published in the journal Nature Communications.
-
MiMedx Appoints Mark Graves Chief Compliance Officer To Strengthen Corporate Compliance Practices
7/18/2018
Board and Management Continue to Take Action to Improve Internal Practices
-
Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease
7/18/2018
Results showed a significant improvement in these measures: lower median number of sickle cell crises, fewer hospitalizations, lower cumulative days in hospital, and lower incidence of acute chest syndrome
-
Bioceutical Manufacturer Launches Products To Enhance Immune System, Increase Energy
7/18/2018
Miami-based ScimeraMD has announced the launch of two new physician-formulated, natural products that can enhance the immune system and increase energy.
-
ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018
7/18/2018
ArQule, Inc. announced it will report financial results for the second quarter of 2018 before the market opens on Wednesday, August 1, 2018.
-
Genprex To Present At The Singular Research Summer Solstice 2018 Conference
7/18/2018
Genprex, Inc. announced that Rodney Varner, Chairman and Chief Executive Officer, will present at the Singular Research Summer Solstice 2018 Conference to be held on July 19th in New York, New York.